Desvenlafaxine
Other / unclassified targets SLC6A2, SLC6A4 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | PRISTIQ | — | 2013-02-14 – 2018-02-06 | fda.gov ↗ |
| Approved | US (FDA) | PRISTIQ | — | 2008-02-29 | fda.gov ↗ |
Trials 68 · started per year
Also used as a comparator or background therapy in 19 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02988024 Comparator | Dec 2016 | major depressive disorder | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02055300 Comparator | Feb → Aug 2014 | major depressive disorder | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00727064 Comparator | Jun → Aug 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03321526 Background | Dec 2017 → Jun 2019 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00797966 Background | May 2009 → Jun 2010 | major depressive disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01803711 Background | Feb 2013 → Jun 2016 | cancer, cardiovascular disorder, diabetes mellitus, major depressive disorder | UConn Health | Terminated | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT04476030 Background | Nov 2020 → Oct 2021 | major depressive disorder | Biogen | Completed | No outcome recorded |
| Phase 3 | NCT02400346 Background | Mar 2015 → Jun 2016 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT01838876 Background | Apr 2013 → Jul 2015 | major depressive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT01715805 Background | Nov 2012 → Jun 2016 | major depressive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00824291 Comparator | Feb → Oct 2009 | major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00406640 Comparator | Dec 2006 → Feb 2008 | major depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00401245 Comparator | Dec 2006 → Jan 2008 | — | Pfizer | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT05273996 Background | Sep 2021 → Apr 2027 expected | major depressive disorder, neurotic disorder | David Steffens | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04448431 Comparator | Jun 2020 → Jan 2022 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 4 | NCT02859103 Comparator | Jun 2017 → Nov 2019 | atypical depressive disorder, depressive disorder | Unity Health Toronto | Completed | No outcome recorded |
| Phase 4 | NCT01056289 Comparator | Mar 2010 → Feb 2011 | major depressive disorder | Pfizer | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06270433 Comparator | Feb → Dec 2024 | atypical depressive disorder | Jiangsu Province Nanjing Brain Hospital | Unknown | No outcome recorded |
| — | NCT01468610 Comparator | Jan 2012 → Sep 2014 | major depressive disorder | University of British Columbia | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-03-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of Generic Pristiq® in the United States tevapharm.com ↗ |
| 2015-06-11 | Pfizer | Pfizer Reports Top Line Results from a Phase 3 Study Evaluating Desvenlafaxine Succinate Sustained-Release Formulation in Pediatric Patients with Major Depressive Disorder pfizer.com ↗ |
Evidence & citations 34 cited values
Every value below carries the sentence it was read from. 100 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | desvenlafaxine | “ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its...” NCT01838876 ↗74“Citalopram, ecitalopram, fluoxetine, sertraline, paroxetine IR, paroxetine CR, venlafaxine IR, venlafaxine XR (extended release), desvenlafaxine, duloxetine, mirtazapine,...” NCT02400346 ↗ “This is a 6-month, open-label, flexible-dose study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Child and Adolescent Outpatients with...” NCT01371708 ↗ “We made other SSRIs (escitalopram, sertraline) and SNRIs (desvenlafaxine, duloxetine, venlafaxine) our third-line antidepressants, given their negligible effects on weight.” NCT04437485 ↗ “ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.” NCT01715805 ↗ “Participants will receive SNRI antidepressant (such as duloxetine, milnacipran, levomilnacipran, venlafaxine, desvenlafaxine) as a part of background therapy” NCT03321526 ↗ “OBJECTIVE: To compare efficacy and safety of desvenlafaxine succinate (desvenlafaxine) with placebo for the treatment of vasomotor symptoms.” PMID 18165395 ↗ Jan 2008 “the serotonin-norepinephrine reuptake inhibitor desvenlafaxine in adults with painful diabetic peripheral neuropathy (DPN)” PMID 25018648 ↗ Jun 2014 “Desvenlafaxine significantly improved symptoms of depression versus placebo regardless of baseline BMI.” PMID 26644956 ↗ Jun 2015 “which included escitalopram, sertraline, and desvenlafaxine in a prescribed sequence.” PMID 27788313 ↗ Oct 2016 “desvenlafaxine succinate sustained release (DVS SR)” NCT00445679 ↗ “flexible-dose desvenlafaxine (20-50 mg/d)” PMID 30419989 ↗ Oct 2019 “Desvenlafaxine (Pristiq)” NCT00797966 ↗ “Desvenlafaxine, Pristiq” NCT01916824 ↗ |
| Known as | D-veniz | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | DESV | “Desvenlafaxine (DESV) is a SNRI with minimal cardiotoxicity and drug interactions.” PMID 29738425 ↗ Sep 2018 |
| Known as | Desvenlafaxina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | DESVENLAFAXINE FUMARATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | Desvenlafaxine fumarate anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | Desvenlafaxine SR | “Period 2-Desvenlafaxine SR 100mg on days 1-19 with coadministration of Aripiprazole 5mg on day 7.” NCT01188668 ↗ |
| Known as | desvenlafaxine succinate | “The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS SR, an extended release form of desvenlafaxine succinate, in comparison to placebo...” NCT00369434 ↗19“In an effort to establish the lowest effective dose of desvenlafaxine (administered as desvenlafaxine succinate), we assessed the efficacy, safety, and tolerability of 10- and...” PMID 23517291 ↗ Mar 2013 “The aim of this study was to evaluate open-label desvenlafaxine treatment (administered as desvenlafaxine succinate) in postmenopausal women who did not achieve clinical...” PMID 21323394 ↗ Mar 2011 “The primary objective was to evaluate the long-term safety of desvenlafaxine (administered as desvenlafaxine succinate) during open-label treatment in adult outpatients with a...” PMID 21977353 ↗ 2011 “OBJECTIVE: A previous trial of the serotonin-norepinephrine reuptake inhibitor desvenlafaxine (administered as desvenlafaxine succinate) raised concerns on potential serious...” PMID 23266840 ↗ Jan 2013 “The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are...” NCT00256685 ↗ “Study Comparing Discontinuation Symptoms in subjects with Major Depressive Disorder treated for 24 Weeks with Open-label 50 mg Desvenlafaxine Succinate Sustained-Release...” NCT01056289 ↗ “BACKGROUND: This study evaluated the efficacy and safety of low-dose desvenlafaxine (administered as desvenlafaxine succinate) in treating major depressive disorder (MDD).” PMID 23334675 ↗ Jan 2013 “This randomized, double-blind, placebo-controlled trial evaluated the short-term efficacy and safety of desvenlafaxine (administered as desvenlafaxine succinate)” PMID 20797382 ↗ Aug 2010 “Desvenlafaxine Succinate Sustained-Release Tablet 50 mg+Duloxetine Hydrochloride Enteric-coated Capsule Placebo 60 mg orally once daily for 8 weeks.” NCT04364997 ↗ “OBJECTIVE: To compare efficacy and safety of desvenlafaxine succinate (desvenlafaxine) with placebo for the treatment of vasomotor symptoms.” PMID 18165395 ↗ Jan 2008 “Desvenlafaxine succinate (DVS SR) is a serotonin and norepinephrine reuptake inhibitor (SNRI).” NCT00401245 ↗ “desvenlafaxine (administered as desvenlafaxine succinate)” PMID 19142106 ↗ Feb 2009 “desvenlafaxine succinate sustained-release (DVS SR) 50mg” NCT00283842 ↗ “Desvenlafaxine Succinate Sustained-Release (DVS SR)” NCT00619619 ↗ “desvenlafaxine succinate sustained release (DVS SR)” NCT00445679 ↗ “Desvenlafaxine succinate sustained-release tablets” NCT06270433 ↗ “Drug: Desvenlafaxine Succinate” NCT01974934 ↗ “Desvenlafaxine succinate 100mg” NCT02819921 ↗ |
| Known as | Desvenlafaxine succinate anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | Desvenlafaxine succinate hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | Desvenlafaxine succinate monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | desvenlafaxine succinate sustained-release | “A multicenter, 10-week study to evaluate the efficacy and safety of 50 mg of desvenlafaxine succinate sustained-release formulation (DVS SR) versus placebo in the treatment of...” NCT01121484 ↗4“This is a multicenter study to assess the health and well-being in subjects who are outpatients with major depressive disorder that take desvenlafaxine succinate sustained...” NCT00824291 ↗ “This is a 6-month, open-label, flexible-dose study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Child and Adolescent Outpatients with...” NCT01371708 ↗ “The primary objective is to evaluate the long-term safety of desvenlafaxine succinate sustained-release (DVS SR) during open-label treatment in adult outpatients with...” NCT00424892 ↗ “Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)” NCT01432457 ↗ |
| Known as | Desvenlafaxine Succinate Sustained-Release Tablets | “Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)” NCT00619619 ↗ |
| Known as | Desvenlafaxine, Pristiq | “Desvenlafaxine, Pristiq” NCT01916824 ↗ |
| Known as | DVLX | “We report a study of the serotonin-norepinephrine reuptake inhibitor (SNRI) desvenlafaxine (DVLX) for PDD.” PMID 30423468 ↗ Nov 2018 |
| Known as | DVS | “The purpose of the study is to evaluate the efficacy and safety of Desvenlafaxine Succinate (DVS) Sustained Release (SR), in comparison to placebo for the treatment of...” NCT00683800 ↗3“The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are...” NCT00256685 ↗ “Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI).” NCT00369343 ↗ “Desvenlafaxine succinate (DVS) has been developed for the treatment of MDD.” NCT00888862 ↗ |
| Known as | Dvs anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | DVS SR | “The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS SR, an extended release form of desvenlafaxine succinate, in comparison to placebo...” NCT00369434 ↗23“A multicenter, 10-week study to evaluate the efficacy and safety of 50 mg of desvenlafaxine succinate sustained-release formulation (DVS SR) versus placebo in the treatment of...” NCT01121484 ↗ “An Open-Label, Two-Period, Sequential Drug Interaction Study to Evaluate the Effect of Multiple Doses of Desvenlafaxine Succinate Sustained Release (DVS SR) on the...” NCT00952653 ↗ “This is a multicenter study to assess the health and well-being in subjects who are outpatients with major depressive disorder that take desvenlafaxine succinate sustained...” NCT00824291 ↗ “This is a 6-month, open-label, flexible-dose study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Child and Adolescent Outpatients with...” NCT01371708 ↗ “This is a double-blind study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) versus placebo in the Treatment of Children and Adolescent Outpatients with Major...” NCT01371734 ↗ “This is a Double-blind Study Evaluating Desvenlafaxine Succinate (DVS SR) Sustained Release vs Placebo in the Treatment of Children and Adolescent Outpatients with Major...” NCT01372150 ↗ “Study Comparing Discontinuation Symptoms in subjects with Major Depressive Disorder treated for 24 Weeks with Open-label 50 mg Desvenlafaxine Succinate Sustained-Release...” NCT01056289 ↗ “The primary objective is to evaluate the long-term safety of desvenlafaxine succinate sustained-release (DVS SR) during open-label treatment in adult outpatients with...” NCT00424892 ↗ “A Randomized, Open-Label, Cross-Over Drug Interaction Study to Evaluate the Effects of Desvenlafaxine (DVS SR) and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects” NCT00329147 ↗ “Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)” NCT01432457 ↗ “Desvenlafaxine succinate (DVS SR) is a serotonin and norepinephrine reuptake inhibitor (SNRI).” NCT00401245 ↗ “Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)” NCT00369343 ↗ “multiple oral doses of desvenlafaxine sustained release (DVS SR) and paroxetine” NCT00456898 ↗ “desvenlafaxine succinate sustained-release (DVS SR) 50mg” NCT00283842 ↗ “Desvenlafaxine Succinate Sustained-Release (DVS SR)” NCT00798707 ↗ “Desvenlafaxine Succinate Sustained-Release (DVS SR)” NCT00384033 ↗ “Desvenlafaxine Succinate Sustained-Release (DVS SR)” NCT00619619 ↗ “Desvenlafaxine Succinate Sustained-Release (DVS SR)” NCT00727064 ↗ “desvenlafaxine succinate sustained release (DVS SR)” NCT00397176 ↗ “Desvenlafaxine succinate sustained-release (DVS SR)” NCT00406640 ↗ “desvenlafaxine succinate sustained release (DVS SR)” NCT00445679 ↗ “Desvenlafaxine Sustained Release (DVS SR)” NCT00440427 ↗ “Desvenlafaxine Sustained Release (DVS SR)” NCT00696787 ↗ |
| Known as | DVS-233 | “DVS-233 SR (desvenlafaxine sustained release )” NCT00452595 ↗ |
| Known as | DVS-233 SR | “The purpose of this study is to assess the efficacy and safety of 4 doses of desvenlafaxine-233 sustained release (DVS-233 SR) as compared to placebo for the treatment of...” NCT00421031 ↗ |
| Known as | Khedezla | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | Mdd-xr | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | Newven | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | O-desmethyl venlafaxine succinate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | O-desmethylvenlafaxine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | O-desmethylvenlafaxine (odv) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | O-desmethylvenlafaxine fumarate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Known as | Pristiq | “Desvenlafaxine (Pristiq)” NCT00797966 ↗ |
| Known as | WY-45233 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1118 ↗ |
| Action | Inhibit | “the serotonin-norepinephrine re-uptake inhibitor desvenlafaxine” PMID 25758058 ↗ Mar 2015 |
| Modality | Other / unclassified | “the serotonin-norepinephrine reuptake inhibitor (SNRI) desvenlafaxine” PMID 30423468 ↗ Nov 2018 |
| Route | Oral | “4 Fixed Oral Doses” NCT00283842 ↗ |
| Target | SLC6A2 | “Norepinephrine transporter inhibitor” CHEMBL1118 ↗ |
| Target | SLC6A4 | “Serotonin transporter inhibitor” CHEMBL1118 ↗ |